$1.96
5.95% today
Nasdaq, Jun 30, 10:03 pm CET
ISIN
US1511901050
Symbol
CELU

Celularity Inc - Ordinary Shares - Class A Stock price

$1.96
-0.15 7.11% 1M
-0.09 4.39% 6M
-0.12 5.77% YTD
-1.23 38.56% 1Y
-32.04 94.24% 3Y
-100.04 98.08% 5Y
-96.04 98.00% 10Y
-96.04 98.00% 20Y
Nasdaq, Closing price Mon, Jun 30 2025
+0.11 5.95%
ISIN
US1511901050
Symbol
CELU
Sector
Industry

Key metrics

Basic
Market capitalization
$44.3m
Enterprise Value
$85.9m
Net debt
$41.6m
Cash
$740.0k
Shares outstanding
22.6m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
0.82 | 0.66
EV/Sales
1.58 | 1.28
EV/FCF
negative
P/B
4.72
Financial Health
Equity Ratio
6.65%
Return on Equity
-654.89%
ROCE
-48.19%
ROIC
-36.78%
Debt/Equity
4.78
Financials (TTM | estimate)
Revenue
$54.2m | $66.8m
EBITDA
$-36.3m | -
EBIT
$-38.1m
Net Income
$-57.9m | $-9.7m
Free Cash Flow
$-8.1m
Growth (TTM | estimate)
Revenue
138.12% | 23.29%
EBITDA
-732.75% | -
EBIT
-1,173.96%
Net Income
70.51% | 83.31%
Free Cash Flow
81.28%
Margin (TTM | estimate)
Gross
72.36%
EBITDA
-66.98% | -
EBIT
-70.22%
Net
-106.75% | -14.45%
Free Cash Flow
-14.87%
More
EPS
$-2.59
FCF per Share
$-0.36
Short interest
31.68%
Employees
120.00
Rev per Employee
$450.00k
Show more

Is Celularity Inc - Ordinary Shares - Class A a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,948 stocks worldwide.

Celularity Inc - Ordinary Shares - Class A Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Celularity Inc - Ordinary Shares - Class A forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Celularity Inc - Ordinary Shares - Class A forecast:

Buy
86%
Hold
14%

Financial data from Celularity Inc - Ordinary Shares - Class A

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
54 54
138% 138%
100%
- Direct Costs 15 15
6% 6%
28%
39 39
480% 480%
72%
- Selling and Administrative Expenses 59 59
16% 16%
108%
- Research and Development Expense 17 17
43% 43%
32%
-36 -36
733% 733%
-67%
- Depreciation and Amortization 1.76 1.76
20% 20%
3%
EBIT (Operating Income) EBIT -38 -38
1,174% 1,174%
-70%
Net Profit -58 -58
71% 71%
-107%

In millions USD.

Don't miss a Thing! We will send you all news about Celularity Inc - Ordinary Shares - Class A directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Celularity Inc - Ordinary Shares - Class A Stock News

Neutral
GlobeNewsWire
20 days ago
Celularity retains financial and business advisor to provide outsourced accounting and consulting services during the transition period Celularity retains financial and business advisor to provide outsourced accounting and consulting services during the transition period
Neutral
GlobeNewsWire
28 days ago
Highlights the unique potential of Celularity's proprietary advanced biomaterial technology as a novel cellular delivery system for ocular surface reconstruction Supports broad range of regenerative medicine applications beyond ophthalmology FLORHAM PARK, N.J., June 02, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative and cellular medicine ...
Neutral
GlobeNewsWire
about one month ago
FLORHAM PARK, N.J., May 30, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a cellular and regenerative medicine company, today announced that on May 28, 2025, Nasdaq notified the Company that it did not timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2025. Based on this latest notice, the Company is not in compliance with Li...
More Celularity Inc - Ordinary Shares - Class A News

Company Profile

Celularity, Inc. a clinical stage biotechnology company, discovers cancer sub-types and therapeutic options for cancer patients in the United States. The firms CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. It is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. The company is headquartered in Florham Park, NJ.

Head office United States
CEO Robert Gordon
Employees 120
Founded 2016
Website celularity.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today